NASDAQ:ASLN

ASLAN Pharmaceuticals Stock Forecast, Price & News

$3.07

-0.28 (-8.36 %)

(As of 04/12/2021 12:00 AM ET)

Add

Compare

Today's Range

$3.01

Now: $3.07▼

$3.37

50-Day Range

$3.25

MA: $3.79▼

$5.25

52-Week Range

$1.26

Now: $3.07▼

$6.75

Volume525,032 shs

Average Volume2.12 million shs

Market Capitalization$116.63 million

P/E RatioN/A

Dividend YieldN/A

Beta2.49

ASLAN Pharmaceuticals Limited, a clinical-stage immunology and oncology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and a small molecule inhibitor targeting oncology. Its partners include Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ASLN

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.aslanpharma.com

Phone65-6222-4235

EmployeesN/A

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio2.08

Quick Ratio2.08

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$3 million

Price / Sales38.88

Cash FlowN/A

Price / Cash FlowN/A

Book Value($0.02) per share

Price / Book-153.50

Profitability

EPS (Most Recent Fiscal Year)($0.74)

Net Income$-47,020,000.00

Net MarginsN/A

Return on Equity-10,427.34%

Return on Assets-97.68%

Miscellaneous

Outstanding Shares37,991,000

Market Cap$116.63 million

Next Earnings Date5/10/2021 (Estimated)

OptionableNot Optionable

Headlines

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) Expected to Announce Earnings of -$0.11 Per Share
April 5, 2021 | americanbankingnews.com

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) Sees Significant Growth in Short Interest
March 26, 2021 | americanbankingnews.com

ASLAN Pharmaceuticals (NASDAQ:ASLN) Given New $8.00 Price Target at HC Wainwright
March 23, 2021 | americanbankingnews.com

What Makes ASLAN Pharmaceuticals Ltd. (ASLN) a New Buy Stock
March 10, 2021 | finance.yahoo.com

Stock Alert: ASLAN Pharma Jumps 30% On Positive Data From Atopic Dermatitis Treatment Study
March 1, 2021 | markets.businessinsider.com

Aslan Pharma Jumps on Progress With Dermatitis Treatment
March 1, 2021 | msn.com

Aslan Pharmaceuticals Shares Are Trading Higher On Positive ASLAN004 Data In Atopic Dermatitis
March 1, 2021 | finance.yahoo.com

ASLAN Pharmaceuticals Announces Positive Interim Data From the Multiple Ascending Dose Study of ASLAN004 in Atopic Dermatitis
March 1, 2021 | finance.yahoo.com

ASLAN Pharmaceuticals Announces $18 Million Private Placement
February 25, 2021 | finance.yahoo.com

ASLAN Pharmaceuticals Limited (ASLN)
January 27, 2021 | uk.finance.yahoo.com

New Research Published in Toxicology in Vitro Provides Insight Into the Hepatotoxicity of DHODH Inhibitors Suggesting ASLAN003 Has the Potential to Be Best-In-Class
January 26, 2021 | finance.yahoo.com

ASLAN Pharmaceuticals Opens Expansion Cohort in ASLAN004 Atopic Dermatitis Clinical Trial
January 11, 2021 | finance.yahoo.com

Aerpio (ARPO) Seeks Strategic Options for Pipeline Programs
January 6, 2021 | finance.yahoo.com

ASLAN Pharmaceuticals Ltd. (ASLN) Moves to Buy: Rationale Behind the Upgrade
December 25, 2020 | finance.yahoo.com

Intellia (NTLA) Catches Eye: Stock Jumps 7.8%
December 3, 2020 | finance.yahoo.com

ORIC Pharmaceuticals (ORIC) in Focus: Stock Moves 6.7% Higher
December 1, 2020 | finance.yahoo.com

Is ASLAN Pharmaceuticals Limited (ASLN) A Good Stock To Buy?
November 29, 2020 | finance.yahoo.com

HorizonTherapeutics (HZNP) Rises YTD on Approvals & Buyouts
November 27, 2020 | finance.yahoo.com

Amgen (AMGN) Ends Deal With Cytokinetics for Heart Candidate
November 24, 2020 | finance.yahoo.com

Horizon (HZNP) and Halozyme Ink Deal for ENHANZE Technology
November 24, 2020 | finance.yahoo.com

See More Headlines

MarketRank^™

Overall MarketRank^™

1.16 out of 5 stars

Medical Sector

949th out of 2,016 stocks

Pharmaceutical Preparations Industry

451st out of 771 stocks

3.5 Analyst's Opinion

Consensus Rating
ASLAN Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.00, ASLAN Pharmaceuticals has a forecasted upside of 159.7% from its current price of $3.08.
Amount of Analyst Coverage
ASLAN Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

2.3 Community Rank

Outperform Votes
ASLAN Pharmaceuticals has received 181 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
ASLAN Pharmaceuticals has received 205 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
ASLAN Pharmaceuticals has received 53.11% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about ASLAN Pharmaceuticals and other stocks. Vote “Outperform” if you believe ASLN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ASLN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
ASLAN Pharmaceuticals does not currently pay a dividend.
Dividend Growth
ASLAN Pharmaceuticals does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ASLAN Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 10.64% of the stock of ASLAN Pharmaceuticals is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for ASLAN Pharmaceuticals are expected to decrease in the coming year, from ($0.40) to ($0.57) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ASLAN Pharmaceuticals is -2.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ASLAN Pharmaceuticals is -2.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

$3.07

-0.28 (-8.36 %)

(As of 04/12/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive ASLN News and Ratings via Email

Sign-up to receive the latest news and ratings for ASLN and its competitors with MarketBeat's FREE daily newsletter.

ASLAN Pharmaceuticals (NASDAQ:ASLN) Frequently Asked Questions

Is ASLAN Pharmaceuticals a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ASLAN Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ASLAN Pharmaceuticals stock.
View analyst ratings for ASLAN Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than ASLAN Pharmaceuticals?

Wall Street analysts have given ASLAN Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ASLAN Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting ASLAN Pharmaceuticals?

ASLAN Pharmaceuticals saw a increase in short interest in March. As of March 15th, there was short interest totaling 1,200,000 shares, an increase of 13,693.1% from the February 28th total of 8,700 shares. Based on an average trading volume of 2,120,000 shares, the short-interest ratio is currently 0.6 days.
View ASLAN Pharmaceuticals' Short Interest.

When is ASLAN Pharmaceuticals' next earnings date?

ASLAN Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for ASLAN Pharmaceuticals.

How were ASLAN Pharmaceuticals' earnings last quarter?

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) released its earnings results on Saturday, November, 14th. The company reported ($0.10) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.01.
View ASLAN Pharmaceuticals' earnings history.

How has ASLAN Pharmaceuticals' stock price been impacted by Coronavirus?

ASLAN Pharmaceuticals' stock was trading at $1.59 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ASLN stock has increased by 93.1% and is now trading at $3.07.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for ASLN?

1 brokers have issued 12 month price targets for ASLAN Pharmaceuticals' stock. Their forecasts range from $8.00 to $8.00. On average, they expect ASLAN Pharmaceuticals' share price to reach $8.00 in the next year. This suggests a possible upside of 160.6% from the stock's current price.
View analysts' price targets for ASLAN Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are ASLAN Pharmaceuticals' key executives?

ASLAN Pharmaceuticals' management team includes the following people:

Dr. Carl Alan Jason Morton Firth, CEO & Exec. Director (Age 48)
Mr. Kiran Kumar Asarpota, Chief Operating Officer (Age 42)
Mr. Ben Goodger, Gen. Counsel (Age 58)
Charlie Hsu, Investor Relations Director
Chi-Chin Wang, IR & Corp. Devel. Director
Ms. Alison Ward, Chief Devel. Officer
Mr. Stephen Doyle, Chief Bus. Officer (Age 48)
Dr. Kenneth Kobayashi, Chief Medical Officer

Who are some of ASLAN Pharmaceuticals' key competitors?

Some companies that are related to ASLAN Pharmaceuticals include Forte Biosciences (FBRX), Akebia Therapeutics (AKBA), Summit Therapeutics (SMMT), Geron (GERN), Spectrum Pharmaceuticals (SPPI), Foghorn Therapeutics (FHTX), Catalyst Pharmaceuticals (CPRX), Verastem (VSTM), Inozyme Pharma (INZY), Applied Therapeutics (APLT), Molecular Templates (MTEM), CytomX Therapeutics (CTMX), Viking Therapeutics (VKTX), XOMA (XOMA) and Selecta Biosciences (SELB).
View all of ASLN's competitors.

What other stocks do shareholders of ASLAN Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ASLAN Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Arbutus Biopharma (ABUS), Allena Pharmaceuticals (ALNA), Actinium Pharmaceuticals (ATNM), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Onconova Therapeutics (ONTX), Aldeyra Therapeutics (ALDX), SCYNEXIS (SCYX) and VBI Vaccines (VBIV).

When did ASLAN Pharmaceuticals IPO?

(ASLN) raised $60 million in an IPO on Friday, May 4th 2018. The company issued 7,500,000 shares at a price of $8.05 per share. Leerink Partners and Piper Jaffray served as the underwriters for the IPO and BTIG, H.C. Wainwright and CLSA were co-managers.

What is ASLAN Pharmaceuticals' stock symbol?

ASLAN Pharmaceuticals trades on the NASDAQ under the ticker symbol "ASLN."

How do I buy shares of ASLAN Pharmaceuticals?

Shares of ASLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ASLAN Pharmaceuticals' stock price today?

One share of ASLN stock can currently be purchased for approximately $3.07.

How much money does ASLAN Pharmaceuticals make?

ASLAN Pharmaceuticals has a market capitalization of $116.63 million and generates $3 million in revenue each year. The company earns $-47,020,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis.

What is ASLAN Pharmaceuticals' official website?

The official website for ASLAN Pharmaceuticals is www.aslanpharma.com.

Where are ASLAN Pharmaceuticals' headquarters?

ASLAN Pharmaceuticals is headquartered at 83 CLEMENCEAU AVENUE 12-03 UE SQUARE, SINGAPORE U0, 239920.

How can I contact ASLAN Pharmaceuticals?

ASLAN Pharmaceuticals' mailing address is 83 CLEMENCEAU AVENUE 12-03 UE SQUARE, SINGAPORE U0, 239920. The company can be reached via phone at 65-6222-4235 or via email at [email protected]

This page was last updated on 4/12/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here